Creative Medical Technology Holdings, Inc. (CELZ) Stock

Creative Medical Technology Holdings, Inc. (CELZ) is a Healthcare stock trading at $1.31 (as of 2026-08-21), with a market capitalization of $8.64M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Creative Medical Technology Holdings, Inc. is a biotechnology company focused on areas including immunology, urology, orthopedics, and neurology, using adult stem cell-based therapies. Its product candidates include CaverStem, FemCelz, StemSpine, ImmCelz, and OvaStem, which are aimed at indications such as erectile dysfunction, loss of genital sensitivity and dryness, chronic lower back pain, stroke, and female infertility.

Understand Creative Medical Technology Holdings, Inc.: how it makes money

Creative Medical Technology Holdings develops and offers adult stem cell treatments for conditions in immunology, urology, orthopedics, and neurology, including CaverStem, FemCelz, StemSpine, ImmCelz, and OvaStem.

The company’s commercial and financial outcome is tied to whether its adult stem cell treatment programs across multiple named indications (CaverStem, FemCelz, StemSpine, ImmCelz, OvaStem) generate ongoing demand and revenue.

Business quality (Weak): Clear view of product focus and therapeutic areas, but limited investor visibility here on reportable segments and operational KPIs, and the latest quarter shows extreme negative operating profitability.

Bull case

  • Multiple adult stem cell treatment programs across several therapeutic areas: The company offers treatments spanning immunology, urology, orthopedics, and neurology with named products targeting different conditions (for example, erectile dysfunction, loss of genital sensitivity and dryness, chronic lower back pain, stroke, and female infertility).
  • Gross margin reported as positive in the latest quarter: For the quarter ended 2025-03-31, gross_margin_pct is 60.0%, indicating a positive gross profit figure in the provided financial snapshot.

Bear case

  • Extreme negative operating profitability: For the quarter ended 2025-03-31, operating_margin_pct is -55349.3%, indicating very large losses at the operating level in the provided data.
  • No operating KPIs or reportable segments provided in the dataset: There is no segment revenue breakdown and no operational KPI list here, which makes it harder to track the specific operating drivers that would explain performance changes.
Valuation — source: SEC EDGAR (first-party)
Price$1.31
Market Cap$8.64M
Price / Book1.00
Price / Sales2878.75
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$6000.00
Net Margin-99916.8%
Revenue Growth (YoY)-100.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.96 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGEODE CAPITAL MANAGEMENT, LLC ($78891.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOTimothy Warbington
Employees4
CountryUS
IPO Date2015-11-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Jasper Therapeutics, Inc. (JSPR)
  • Intensity Therapeutics, Inc. (INTS)
  • Passage Bio, Inc. (PASG)
  • IN8bio, Inc. (INAB)
  • Senti Biosciences, Inc. (SNTI)
  • VivoSim Labs, Inc. (VIVS)
  • AIM ImmunoTech Inc. (AIM)
  • Calidi Biotherapeutics, Inc. (CLDI)
CELZ earnings history · CELZ institutional & insider holders · CELZ KPIs & operating metrics · CELZ financials · CELZ investor presentations & press releases · CELZ SEC filings · CELZ peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.